NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Phase 2 Clinical Trial of Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

21-N-0010

Sponsoring Institute

National Institute of Neurological Disorders and Stroke (NINDS)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

Children

Special Instructions

Currently Not Provided

Keywords

MS;
BTK Inhibitor

Recruitment Keyword(s)

None

Condition(s)

Multiple Sclerosis

Investigational Drug(s)

Tolebrutinib

Investigational Device(s)

None

Intervention(s)

Drug: tolebrutinib

Supporting Site

National Institute of Neurological Disorders and Stroke

Background:

Some multiple sclerosis (MS) lesions stay inflamed for very long periods of time. This type of inflammation is not affected by any MS medications. These lesions can lead to slow worsening of MS symptoms. Researchers want to see if a new drug can help.

Objective:

To see if tolebrutinib can help clear inflammation in MS brain lesions.

Eligibility:

Adults ages 18 and older with MS who are on an anti-CD20 therapy.

Design:

Participants will be screened under protocol #89-N-0045.

Participants will have a medical history. They will have physical and neurological exams. They will have blood and urine tests. The progression of their MS will be assessed.

Participants will have MRIs of the brain. The MRI scanner is shaped like a cylinder. It uses a magnetic field and radio waves to take pictures of the body. During the MRIs, participants will lie on a table that slides in and out of the scanner. Soft padding or a coil will be placed around their head.

Participants may have electrocardiograms to measure the heart s electrical activity.

Participants may have lumbar punctures ( spinal taps ). A small needle will be inserted into the spinal canal in the lower back. Fluid will be collected.

Some participants will take tolebrutinib pills by mouth once a day for at least 96 weeks. They will stop their anti-CD20 therapy. They will have at least 10 study visits.

Some participants will not take tolebrutinib. They will stay on their anti-CD20 therapy. They will have 5 study visits.

Participation will last at least 96 weeks.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

Tolebrutinib Cohort Inclusion Criteria

1. Able to provide informed consent

2. Willingness to comply with all study procedures and availability for the duration of the study

3. Male or female, aged greater than or equal to 18

4. Diagnosed with multiple sclerosis according to the 2017 revision of the McDonald diagnostic criteria, with no new lesion formation by comparison of baseline MRI scan with a historical MRI scan at least 6 months prior

5. On intravenous anti-CD20 antibody treatment (specifically ocrelizumab or rituximab) for at least 6 months, with the most recent dose at most 6 months prior to enrollment.

6. Willing to forego further anti-CD20 antibody treatment for the duration of the study

7. Has a prior 7-tesla MRI scan, no more than 1 year prior to enrollment, demonstrating at least one white matter lesion with a paramagnetic rim

8. For females of reproductive potential: agrees to use highly effective contraception for at least 1 month prior to dosing and to use such a method during study participation and for an additional 12 weeks after the end of tolebrutinib administration

9. For males of reproductive potential: agrees to use condoms or other methods to ensure effective contraception with partner; agrees not to donate sperm from the inclusion up to 12 weeks after the last dose

10. QuantiFERON-TB Gold negative; skin testing (e.g., tuberculin skin test) will be allowed if blood testing is not available or the blood test result is indeterminate

11. Agrees to adhere to Lifestyle Considerations throughout study duration

12. Agrees not to participate in any other interventional study while participating in this protocol

Control Cohort Inclusion Criteria:

1. Able to provide informed consent

2. Willingness to comply with all study procedures and availability for the duration of the study

3. Male or female, aged greater than or equal to 18

4. Diagnosed with multiple sclerosis according to the 2017 revision of the McDonald diagnostic criteria, with no new lesion formation by comparison of baseline MRI scan with a historical MRI scan at least 6 months prior

5. On intravenous anti-CD20 antibody treatment (specifically intravenous ocrelizumab or rituximab) for at least 6 months, with the most recent dose at most 6 months prior to enrollment. (Participants in this cohort should not be on ofatumumab, another anti-CD20 treatment, at baseline, but they may switch from ocrelizumab or rituximab to ofatumumab after week 48.)

6. Has a prior 7-tesla MRI scan, no more than 1 year prior to enrollment, demonstrating at least one white matter lesion with a paramagnetic rim

7. For females of reproductive potential: agrees to use highly effective contraception during study participation

8. Agrees not to participate in any other interventional study while participating in this protocol

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

Tolebrutinib Cohort Exclusion Criteria

1. Pregnancy or lactation

2. MS relapse in the 6 months prior to dosing

3. Febrile illness within 4 weeks prior to dosing, or persistent chronic or active infection requiring treatment with systemic antibiotics, antivirals, or antifungals.

4. Treatment with another investigational drug or other investigational intervention within 3 months prior to baseline

5. Contraindications for 7-tesla MRI

6. Presence of any screening laboratory or ECG values outside normal limits that are considered in the PI or MAI s judgment to be clinically significant, including but not limited to:

a. Presence of liver injury defined as underlying hepatobiliary disease or screening alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal (ULN)

b. At screening, positive for hepatitis B surface antigen and/or hepatitis B core antibody and/or positive for hepatitis C antibody

c. Any of the following:

--Bleeding disorder or known platelet dysfunction at any time prior to the first screening visit

--Platelet count less than 150,000/microL at the screening visit

d. Lymphocyte count less than 1000 cells/dL at the screening visit

7. Is HIV-positive

8. Has received any live (attenuated) vaccine (including but not limited to varicella zoster, oral polio, and nasal influenza) within 2 months before dosing

9. Has received any of the following medications/treatments within the specified time frame before baseline assessment:

-Medication: Systemic corticosteroids, adrenocorticotropic hormone; Exclusionary if used/used within required wash-out period: 1 month prior to baseline MRI scan

-Medication: Dimethyl fumarate; Exclusionary if used/used within required wash-out period: 6 months prior to dosing

-Medication: Intravenous immunoglobulin, fingolimod, natalizumab; Exclusionary if used/used within required wash-out period: 6 months prior to dosing

-Medication: Teriflunomide; Exclusionary if used/used within required wash-out period: 2 years prior to dosing or 1 month prior to dosing

if participant undergoes an accelerated elimination procedure and has documented teriflunomide plasma level below 0.02 mg/L

before dosing

-Medication: Mildly to moderately immunosuppressive/chemotherapeutic medications such azathioprine and methotrexate; Exclusionary if used/used within required wash-out period: 6 months prior to dosing

-Medication: Highly immunosuppressive/chemotherapeutic medications: mitoxantrone up to 120 mg/m2 body surface area, cyclophosphamide, cladribine; Exclusionary if used/used within required wash-out period: 2 years prior to dosing

-Medication: Alemtuzumab; Exclusionary if used/used within required wash-out period: 4 years prior to dosing

-Medication: Lymphoid irradiation, bone marrow transplantation, mitoxantrone (with evidence of cardiotoxicity following treatment, or cumulative lifetime dose >120 mg/m2), other strongly immunosuppressive treatments with very long-lasting effects; Exclusionary if used/used within required wash-out period: Any time

-Medication: Any BTK inhibitor; Exclusionary if used/used within required wash-out period: Any time

10. Is receiving strong inducers or inhibitors of CYP3A or CYP2C8 hepatic enzymes

11. Is receiving anticoagulant/antiplatelet therapies, including:

a. Acetylsalicylic acid (aspirin); half-life elimination: Parent drug: Plasma concentration: 15 to 20 minutes; Salicylates (dose dependent): 3 hours at lower doses (300 to 600 mg), 5 to 6 hours (after 1 g), 10 hours with higher doses

b. Antiplatelet drugs (eg, clopidogrel); half-life: 6 hours

c. Warfarin (vitamin K antagonist); half-life: 20-60 hours

d. Heparin, including low molecular weight heparin (antithrombin agents); half-life: 60-90 minutes

e. Dabigatran (direct thrombin inhibitor); half-life:12-17 hours

f. Apixaban (IV half-life: approximately 5 hours, oral half-life: approximately 12 hours), edoxaban (half-life: 10-14 hours), rivaroxaban (half-life: 5-9 or 11-13 hours in younger or elderly individuals, respectively) (direct factor Xa inhibitors)

Note: All above drugs need to be stopped at least 5 half-lives before study drug administration except for aspirin, which needs to be stopped at least 8 days before.

12. Has a history or presence of significant other concomitant illness that, according to the PI or MAI s judgment, would adversely affect participation in this study; examples include but are not limited to clinically significant cardiovascular, renal, hepatic, or metabolic

disease.

13. Unwilling to allow coded samples to be processed offsite

14. Unwilling to have coded samples and/or data saved or used in other studies.

Control Cohort Exclusion Criteria:

1. Pregnancy or lactation

2. MS relapse in the 6 months prior to baseline

3. Treatment with another investigational drug or other investigational intervention within 3 months prior to baseline

4. Contraindications for 7-tesla MRI

5. Has received any of the following medications/treatments within the specified time frame before baseline assessment:

-Medication: Systemic corticosteroids, adrenocorticotropic hormone; Exclusionary if used/used within required wash-out period: 1 month prior to baseline MRI scan

-Medication: Dimethyl fumarate; Exclusionary if used/used within required wash-out period: 6 months prior to dosing

-Medication: Intravenous immunoglobulin, fingolimod, natalizumab; Exclusionary if used/used within required wash-out period: 2 years prior to dosing or 1 month prior to dosing if participant undergoes an accelerated elimination procedure and has documented

teriflunomide plasma level below 0.02 mg/L before dosing

-Medication: Mildly to moderately immunosuppressive/chemotherapeutic medications such azathioprine and methotrexate; Exclusionary if used/used within required wash-out period: 6 months prior to dosing

-Medication: Highly immunosuppressive/chemotherapeutic medications: mitoxantrone up to 120 mg/m2 body surface area, cyclophosphamide, cladribine; Exclusionary if used/used within required wash-out period: 2 years prior to dosing

-Medication: Lymphoid irradiation, bone marrow transplantation, mitoxantrone (with evidence of cardiotoxicity following treatment, or cumulative lifetime dose >120 mg/m2), other strongly immunosuppressive treatments with very long-lasting effects; Exclusionary if used/used within required wash-out period: Any time

-Medication: Any BTK inhibitor; Exclusionary if used/used within required wash-out period: Any time

6. Has a history or presence of significant other concomitant illness that, according to the PI or MAI s judgment, would adversely affect participation in this study; examples include but are not limited to clinically significant cardiovascular, renal, hepatic, or metabolic

disease.

7. Unwilling to allow coded samples to be processed offsite

8. Unwilling to have coded samples and/or data saved or used in other studies


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Daniel S. Reich, M.D.
National Institutes of Health Clinical Center (CC)



Joan M. Ohayon, C.R.N.P.
National Institutes of Health Clinical Center (CC)
BG 10 RM 5C442
10 CENTER DR
BETHESDA MD 20814
(301) 496-3825
eatonj@ninds.nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: 1-866-411-1010
PRPL@cc.nih.gov

Clinical Trials Number:

NCT04742400

--Back to Top--